Lamivudine as an alternative therapy for interferon-resistant chronic hepatitis B and the characteristics of hepatitis B virus: A case report

Tohoku Journal of Experimental Medicine

Volumn 191, Issue 4, 2000, Pages 247-253

  Terui, Yuki ^a   Saito, Takafumi ^a   Watanabe, Hisayoshi ^a   Aoki, Masanori ^a   Haga, Hiroko ^a   Miyano, Shintaro ^a   Takeda, Tadashi ^a   Saito, Koji ^a   Togashi, Hitoshi ^a   Shinzawa, Haruhide ^a   Takahashi, Tsuneo ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Hepatitis B; Interferon; Lamivudine; Precore mutant; YMDD mutant

Indexed keywords

HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; VIRUS DNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD LEVEL; CASE REPORT; CHRONIC HEPATITIS; DISEASE COURSE; DISEASE EXACERBATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FUNCTION; MALE; POINT MUTATION; VIRAL GENETICS;

EID: 0033635961     PISSN: 00408727     EISSN: None     Source Type: Journal    
DOI: 10.1620/tjem.191.247     Document Type: Article

References (18)

1. Aikawa, T., Kanai, K., Kako, M., Kawasaki, T., Hino, K., Iwabuchi, S., Tsubouchi, H., Takehira, Y., Tsuda, F., Okamoto, H., Miyakawa, Y. & Mayumi, M. (1995) Interferon-α 2a for chronic hepatitis B with e antigen or antibody: Comparable antiviral effects on wild-type virus and precore mutant. J. Viral. Hepat., 2, 243-250.
2. Alberti, A. & Fattovich, G. (1994) Interferon therapy for the anti-HBe positive form of chronic hepatitis B. Antiviral Res., 24, 145-153.
3. Borg, F.T., Smorenburg, S., DeMan, R.A., Rietbroek, R.C., Chamuleau, R.A.F.M. & Jones, E.A. (1998) Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of heaptitis B associated with lamivudine therapy. Dig. Dis. Sci., 43, 2267-2270.
4. Brunetto, M.R., Giarin, M., Saracco, G., Oliveri, F., Calvo, P., Capra, G., Randone, A., Abate, M.L., Manzini, P., Capalbo, M., Piantino, P., Verme, G. & Bonino, F. (1993) Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology, 105, 845-850.
5. Chayama, K., Suzuki, Y., Kobayashi, M., Tsubota, A., Hashimoto, M., Miyano, Y., Koike, H., Kobayashi, M., Koida, I., Arase, Y., Saitoh, S., Murashima, N., Ikeda, K. & Kumada, H. (1998) Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology, 27, 1711-1716.
6. Chien, R.N., Liaw, Y.F. & Atkins, M. (1999) Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology, 30, 770-774.
7. Honkoop, P., Man, R.A., Heijtink, R.A., Schalm, S.W. (1995) Hepatitis B reactivation after lamivudine. Lancet, 346, 1156-1157.
8. Ichikawa, T., Takagi, H., Kinoshita, M., Shimoda, R., Nagamine, T. & Mori, M. (1998) Quantitative analysis of hepatitis B virus precore mutant in hepatitis type B. Tohoku J. Exp. Med., 186, 323-333.
9. Kinoshita, M., Seno, T., Fukui, T., Shin, S., Tsubota, A. & Kumada, H. (1994) A detection method for point mutation in the precore region of human hepatitis B virus (HBV)-DNA using mutation-site-specific assay. Clin. Chim. Acta, 228, 83-90.
10. Lai, C.L., Chien, R.N., Leung, N.W.Y., Chang, T.T., Guan, R., Tai, D.I., Ng, K.Y., Wu, P.C., Dent, J.C., Barber, J., Stephenson, S.L. & Gray, D.F. (1998) A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med., 339, 61-68.
11. Mutimer, D., Naoumov, N., Honkoop, P., Marinos, G., Ahmed, M., Man, R., McPhillips, P., Johnson, M., Williams, R., Elias, E. & Schalm, S. (1998) Combination α-interferon and lamivudine therapy for α-inteferon-resistant chronic hepatitis B infection: results of a pilot study. J. Hepatol., 28, 923-929.
12. Nakahori, S., Yokosuka, O., Ehata, T., Chuang, W.L., Imazeki, F., Ito, Y. & Ohto, M. (1995) Detection of hepatitis B virus precore stop codon mutants by selective amplification method: Frequent detection of precore mutants in hepatitis B e antigen positive healthy carriers. J. Gastroenterol. Hepatol., 10, 419-425.
13. Naoumov, N.V., Schneider, R., Grotzinger, T., Jung, M.C., Miska, S., Pape, G.R. & Will, H. (1992) Precore mutant hepatitis B virus infection and liver diseases. Gastroenterology, 102, 538-543.
14. Nevens, F., Main, J., Honkoop, P., Tyrrell, D.L., Barber, J., Sullivan, M.T., Fevery, J., DeMan, R.A. & Thomas, H.C. (1997) Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study. Gastroenterology, 113, 1258-1263.
15. Ono-Nita, S.K., Kato, N., Shiratori, Y., Masaki, T., Lan, K.H., Carrilho, F.J. & Omata, M. (1999) YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection. Hepatology, 29, 939-945.
16. Suzuki, H., Seta, M., Sasaki, M., Tanaka, E., Yamakawa, Y. & Tanikawa, K. (1997) Clinical usefulness of serum HBV DNA measurement with a non radioactive chemiluminescence method. International Hepatology Communications, 6, 324-331.
17. Tassopoulos, N.C., Volpes, R., Pastore, G., Heathcote, J., Buti, M., Goldin, R.D., Hawley, S., Barber, J., Condreay, L., Gray, F. & The Lamivudine Precore Mutant Study Group (1999) Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology, 29, 889-896.
18. Watanabe, H., Shinzawa, H., Shao, L., Saito, T. & Takahashi, T. (1999) Relationship of TT virus infection with prevalence of hepatitis C virus infection and elevated alanine aminotransferase levels. J. Med. Virol., 58, 235-238.